
Cumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors
Caroline was the President of the
Prior to the Council, Caroline was the founding Executive Director of
Currently, Caroline is the Executive Director of NashvilleHealth, an initiative focused on improving the health of citizens of the metropolitan
"I am honored to join the Board of such an innovative and growing company," said
"We are delighted to welcome Caroline to our Board of Directors," said
Caroline's appointment to Cumberland's Board will be effective
About
Cumberland's five marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, for the treatment of pain and fever, Kristalose® (lactulose) for Oral Solution, a prescription laxative, Vaprisol® (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak® for the treatment of H. pylori infection and duodenal ulcer disease. Cumberland is developing Hepatoren® (ifetroban) Injection for the treatment of Hepatorenal Syndrome, Boxaban® (ifetroban) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease, and Vasculan™ (ifetroban) oral capsule for the treatment of systemic sclerosis. Cumberland is dedicated to providing innovative products that improve quality of care for patients.
For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website www.cumberlandpharma.com.
Logo - http://photos.prnewswire.com/prnh/20140505/84325
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-caroline-young-to-join-its-board-of-directors-300282764.html
SOURCE
News Provided by Acquire Media